Andere talen Unity Biotechnology, Inc.

Aandelen

UBX

US91381U2006

Geschatte realtime Cboe BZX Andere beurzen 15:44:40 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,47 ^USD	0,00%		-2,65%	-23,83%

23/04	Unity Biotechnology, Inc. Kondigt uitbreiding aan van de Fase 2b ASPIRE klinische studie waarbij UBX1325 in DME wordt geëvalueerd	CI
16/04	UNITY BIOTECHNOLOGY, INC. : HC Wainwright herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting	14:01
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	23/04
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
North American Morning Briefing : Stocks Seen -2-	02/04
North American Morning Briefing : Markets Steady -2-	26/03
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	06/02
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	06/02
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	12/12
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	12/12
North American Morning Briefing : Stocks Futures -2-	20/11
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	13/11
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Sector Update: Health Care Stocks Rising Late Afternoon	10/11
Sector Update: Health Care	10/11
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall	10/11
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds	10/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Unity Biotechnology, Inc.

Aandelen

UBX

US91381U2006

Andere talen

Filters